NCT00089973 - Study Of Ispinesib In Subjects With Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

August 25, 2006

Study Completion Date

August 25, 2006

Conditions

Neoplasms, Breast

Interventions

DRUG

Ispinesib

Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).

Trial Locations (13)

GSK Investigational Site, Brussels

GSK Investigational Site, Pittsburgh

GSK Investigational Site, Chapel Hill

GSK Investigational Site, Jacksonville

GSK Investigational Site, Indianapolis

GSK Investigational Site, Bandar Tun Razak, Cheras

GSK Investigational Site, Bandar Tun Razak, Cheras

GSK Investigational Site, Singapore

GSK Investigational Site, Singapore

GSK Investigational Site, Southampton

GSK Investigational Site, Manchester

GSK Investigational Site, Newcastle upon Tyne

GSK Investigational Site, London